Cytomedix
-
Cytomedix Announces Registered Direct Offering of Common Stock and Warrants -
11:14 AM Aug 17th, 2009
from web
-
Cytomedix, Inc. Total revenues for the second quarter of 2009 were $569,000 up 33% from total revenues of $428,000 in the 2nd Quarter 2008
8:04 AM Aug 10th, 2009
from web
-
Cytomedix, Inc. product sales during the second quarter, up 165% from the prior year and up 72% from the first quarter
8:03 AM Aug 10th, 2009
from web
-
Cytomedix Second Quarter Financial Results Feature Product Sales Up 72% Over First Quarter
8:02 AM Aug 10th, 2009
from web
-
8/7/09 - Cytomedix (NYSE AMEX: GTF) Files Application With FDA for AutoloGel(tm) System in Orthopedics.
11:35 AM Aug 7th, 2009
from web
-
In addition to the AutoloGel™ System, Cytomedix is actively developing peptides to fight inflammation and initiate angiogenesis.
3:45 PM Aug 4th, 2009
from web
-
Cytomedix currently is preparing IND submissions to be filed in early 2009.
3:26 PM Aug 4th, 2009
from web
-
Oral activity and anti-inflammatory properties of CT-112 have been corroborated by multiple external laboratories
3:25 PM Aug 4th, 2009
from web
-
The CT-112 peptide is derived from human platelet factor 4 (PF4 or CXCL4)
3:24 PM Aug 4th, 2009
from web
-
Cytomedix's CT-112 is an octapeptide sequence with demonstrated anti-inflammatory activity when administered either orally or parenterally.
3:24 PM Aug 4th, 2009
from web
-
Cytomedix develops biologically active regenerative therapies for wound care, angiogenesis, and inflammation.
3:21 PM Aug 4th, 2009
from web
-
Cytomedix, Inc. is a biotechnology company developing advanced tissue regeneration technologies. FDA Approved Wound Care Product NYSE: GTF
8:46 PM Jul 27th, 2009
from web
-
Synergism in Using NPWT With Alternated Applications of Autologous Platelet-derived Growth Factors -
2:34 PM Jul 26th, 2009
from web
-
The AutoloGel(tm) System Was Alternated With Negative Pressure Wound Therapy (NPWT) to Establish Positive Chronic Wound Outcomes
2:32 PM Jul 26th, 2009
from web
-
Cytomedix Announces the Publication of a New AutoloGel(tm) Case Series in the Journal WOUNDS -
2:32 PM Jul 26th, 2009
from web
-
The AutoloGel System harnesses the patient’s natural healing processes with the delivery of a platelet rich plasma gel (PRP)
9:26 AM May 4th, 2009
from web
-
Cytomedix develops biologically active regenerative therapies for wound care, angiogenesis, and inflammation.
9:25 AM May 4th, 2009
from web
-
Visit to learn more about the FDA Approved AutoloGel for use in Chronic Non-Healing Wounds.
12:06 PM Apr 29th, 2009
from web
-
Visit for more information on the FDA Cleared AutoloGel System for use in chronic non-healing wounds.
6:01 PM Apr 24th, 2009
from web
-
Complications of foot ulcers are a leading cause of hospitalization and amputation in patients with diabetes mellitus.
10:30 PM Apr 23rd, 2009
from web
|
- Name Cytomedix, Inc.
- Location Rockville, MD
- Web http://www.Cytome...
- Bio Cytomedix, Inc. is a biotechnology company developing advanced tissue regeneration technologies. AutoloGel - FDA Approved Wound Care Product - NYSE: GTF
|
